These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37832923)

  • 1. Additional Measures After Stopping Nucleoside Analogues in HbeAg-Negative Chronic Hepatitis B: Better But Not Enough.
    Lim SG; Tan YC
    Gastroenterology; 2024 Jan; 166(1):23-24. PubMed ID: 37832923
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comment on "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B".
    Wan YM; Wu HM; Huang SQ; Li HY; Yin HJ
    J Hepatol; 2024 May; 80(5):e229-e230. PubMed ID: 37572795
    [No Abstract]   [Full Text] [Related]  

  • 4. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B.
    Huang CB; Su TH; Kao JH
    Liver Int; 2023 Apr; 43(4):947-948. PubMed ID: 36732913
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to: "A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B'".
    van Bömmel F; Berg T
    J Hepatol; 2024 May; 80(5):e230-e231. PubMed ID: 38110010
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials.
    Bedre RH; Raj U; Misra SP; Varadwaj PK
    Indian J Gastroenterol; 2016 Mar; 35(2):75-82. PubMed ID: 27083430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we stop nucleoside analogues before HBsAg loss?
    Papatheodoridi M; Papatheodoridis G
    J Viral Hepat; 2019 Aug; 26(8):936-941. PubMed ID: 30803099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H; Jia J
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
    Wübbolding M; Lopez Alfonso JC; Lin CY; Binder S; Falk C; Debarry J; Gineste P; Kraft ARM; Chien RN; Maasoumy B; Wedemeyer H; Jeng WJ; Meyer Hermann M; Cornberg M; Höner Zu Siederdissen C
    Hepatol Commun; 2021 Jan; 5(1):97-111. PubMed ID: 33437904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
    Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study.
    Xie Y; Zhu H; Guo Y; Ma Z; Qi X; Yang F; Mao R; Zhang J
    Can J Gastroenterol Hepatol; 2022; 2022():4325352. PubMed ID: 36531834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.